Research Article

Development, validation and application of a liquid chromatography–tandem mass spectrometry method for quantifying lurasidone in dried blood spot samples

SPPSPTM, SVKM's Narsee Monjee Institute of Management Studies, V.L. Mehta Road, Vile Parle (W), Mumbai, 400056, India

Sitec Labs Ltd Plot No. Gen-40, TTC, MIDC Behind Millennium Business Park, Near Nelco, Mahape, New Mumbai, 400710, India

Search for more papers by this author

Vaishali Londhe

*Author for correspondence:

E-mail Address: vaishali.londhe@nmims.edu

https://orcid.org/0000-0003-3718-9858

SPPSPTM, SVKM's Narsee Monjee Institute of Management Studies, V.L. Mehta Road, Vile Parle (W), Mumbai, 400056, India

Search for more papers by this author

Published Online:22 Nov 2023https://doi.org/10.4155/bio-2023-0142

View article

Abstract

Background: A liquid chromatography–tandem mass spectrometry method for quantifying lurasidone in rat dried blood spot (DBS) samples was developed. Method: The analyte was extracted from DBSs using the liquid–liquid extraction method. Chromatographic separation was achieved using a C18, Phenomenex, 150 × 4.6 mm, 3.0 μm column. The mobile phase composed of methanol, acetonitrile and water (70:10:20 v/v/v) with 0.1% heptafluorobutyric acid performed well in terms of reducing the matrix effect and achieving shorter retention time. Result: The method was validated over a concentration range of 5.0 to 1200.0 ng/ml and supported by the evaluation of various validation parameters. Conclusion: This simple, sensitive and specific method proved to be a viable alternative sampling method with reduced logistics and blood sample storage expenses despite analytical challenges.

Graphical abstract

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Ishibashi T, Horisawa T, Tokuda K et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J. Pharmacol. Exp. Ther. 334(1), 171–181 (2010).
Medline CASGoogle Scholar
2. Riva MA, Riva MA. An update of the preclinical profile of lurasidone. 67–72 (2015). www.semanticscholar.org/paper/An-update-of-the-preclinical-profile-of-lurasidone-Riva/3ce439ab544a92612cda304b9b03dd8e43bfc6e6#citing-papers.
Google Scholar
3. Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin. Investig. Drugs 18(11), 1715–1726 (2009).
Medline CASGoogle Scholar
4. Degreef M, Berry EM, Maudens KEK, van Nuijs ALN. Multi-analyte LC–MS/MS quantification of 38 antipsychotics and metabolites in plasma: method validation & application to routine analyses. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1179, (2021).
Google Scholar
5. Koster RA, Niemeijer P, Veenhof H, van Hateren K, Alffenaar JWC, Touw DJ. A volumetric absorptive microsampling LC–MS/MS method for five immunosuppressants and their hematocrit effects. Bioanalysis 11(6), 495–508 (2019).
CASGoogle Scholar
6. Rao RN. Emerging liquid chromatography-mass spectrometry technologies improving dried blood spot analysis. Expert Rev. Proteomics 11(4), 425–430 (2014).
MedlineGoogle Scholar
7. Patteet L, Maudens KE, Sabbe B, Morrens M, De Doncker M, Neels H. High throughput identification and quantification of 16 antipsychotics and 8 major metabolites in serum using ultra-high performance liquid chromatography-tandem mass spectrometry. Clin. Chim. Acta 429, 51–58 (2014).
Medline CASGoogle Scholar
8. Turpin PE, Burnett JEC, Goodwin L, Foster A, Barfield M. Application of the DBS methodology to a toxicokinetic study in rats and transferability of analysis between bioanalytical laboratories. Bioanalysis 2(8), 1489–1499 (2010).
CASGoogle Scholar
9. Sparrow SS, Robinson S, Bolam S et al. Opportunities to minimise animal use in pharmaceutical regulatory general toxicology: a cross-company review. Regul. Toxicol. Pharmacol. 61(2), 222–229 (2011).
MedlineGoogle Scholar
10. ICH Guideline Questions and Answers to ICH S3A. Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies focus on microsampling S3A Q&As final version. • Guideline and regulatory perspectives.
Google Scholar
11. Londhe V, Rajadhyaksha M. Pertinence of microsampling in various nonclinical and clinical studies: the ICH perspective. Bioanalysis 14(17), 1137–1139 (2022). • Guidelines and regulatory perspectives.
CASGoogle Scholar
12. ICH Harmonised Guideline Bioanalytical Method Validation and Study Sample Analysis M10. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2022). • Guidelines and regulatory perspectives.
Google Scholar
13. Denniff P, Spooner N. The effect of hematocrit on assay bias when using DBS samples for the quantitative bioanalysis of drugs. Bioanalysis 2(8), 1385–1395 (2010). • Guidelines and regulatory perspectives.
CASGoogle Scholar
14. Viswanathan CT. Perspectives on microsampling: DBS. Bioanalysis 4(12), 1417–1419 (2012). • Guidelines and regulatory perspectives.
CASGoogle Scholar
15. Timmerman P, White S, Cobb Z et al. Updates from the EBF DBS–microsampling consortium. Bioanalysis 4(16), 1969–1970 (2012). • Guidelines and regulatory perspectives.
CASGoogle Scholar
16. Chapman K, Chivers S, Gliddon D et al. Overcoming the barriers to the uptake of nonclinical microsampling in regulatory safety studies. Drug Discov. Today 19(5), 528–532 (2014).
Medline CASGoogle Scholar
17. Burnett JE. Dried blood spot sampling: practical considerations and recommendation for use with preclinical studies. 3(10), 1099–1107 (2011). •• The applicationsand advantages of dried blood spot (DBS) samples in the determination ofanalyte and/or metaboliteconcentrations.
Google Scholar
18. Wickremsinhe E. Dried blood spot analysis for rat and dog studies: validation, hematocrit, toxicokinetics and incurred sample reanalysis. Bioanalysis 7(7), 869–883 (2015). •• The applications and advantages of DBS samples in the determination of analyte and/or metabolite concentrations.
CASGoogle Scholar
19. Lim MD. Review article: dried blood spots for global health diagnostics and surveillance: opportunities and challenges. Am. J. Trop. Med. Hyg. 99(2), 256–265 (2018).
MedlineGoogle Scholar
20. Chace DH, De Jesús VR, Spitzer AR. Clinical chemistry and dried blood spots: increasing laboratory utilization by improved understanding of quantitative challenges. Bioanalysis 6(21), 2791–2794 (2014).
CASGoogle Scholar
21. Londhe V, Rajadhyaksha M. Opportunities and obstacles for microsampling techniques in bioanalysis: special focus on DBS and VAMS. J. Pharm. Biomed. Anal. 182, 113102 (2020).
Medline CASGoogle Scholar
22. Hannon WH, Therrell BL. History, applications, and healthcare. In: Li WLee MS (Eds). Dried Blood Spots: Applications and Techniques. (2014). http://media.wiley.com/product_data/excerpt/95/11180546/1118054695-1.pdf
Google Scholar
23. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 32(3), 338–343 (1963).
Medline CASGoogle Scholar
24. Baillargeon KR, Brooks JC, Miljanic PR, Mace CR. Patterned dried blood spot cards for the improved sampling of whole blood. ACS Meas. Sci. Au. 2(1), 31–38 (2022).
Medline CASGoogle Scholar
25. Frey BS, Damon DE, Badu-Tawiah AK. Emerging trends in paper spray mass spectrometry: microsampling, storage, direct analysis, and applications. Mass Spectrom. Rev. 39(4), 336–370 (2020).
Medline CASGoogle Scholar
26. Loria F, Manfredi M, Reverter-branchat G, Segura J. Automation of RNA-based biomarker extraction from dried blood spots for the detection of blood doping. Bioanalysis 12(11), 729–736 (2020).
CASGoogle Scholar
27. Olagunju A, Bolaji OO, Amara A et al. Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC–MS/MS. J. Antimicrob. Chemother. 70(2), 555–561 (2015).
Medline CASGoogle Scholar
28. Xie F, De Thaye E, Vermeulen A, Van Bocxlaer J, Colin P. A dried blood spot assay for paclitaxel and its metabolites. J. Pharm. Biomed. Anal. 148, 307–315 (2018).
Medline CASGoogle Scholar
29. Raymundo S, Muller VV, Andriguetti NB et al. Determination of docetaxel in dried blood spots by LC–MS/MS: method development, validation and clinical application. J. Pharm. Biomed. Anal. 157, 84–91 (2018).
Medline CASGoogle Scholar
30. Gandhi A, Beekman C, Parker R, Fang L, Matta MK. Novel and rapid LC–MS/MS method for quantitative analysis of methylphenidate in dried blood spots. Bioanalysis. 10, 839–850 (2018).
CASGoogle Scholar
31. Wilhelm AJ, den Burger JCG, Swart EL. Therapeutic drug monitoring by dried blood spot: progress to date and future directions. Clin. Pharmacokinet. 53(11), 961–973 (2014). • DBS applications in therapeutic drug monitoring.
Medline CASGoogle Scholar
32. AbuRuz S, Al-Ghazawi M, Al-Hiari Y. A simple dried blood spot assay for therapeutic drug monitoring of lamotrigine. Chromatographia 71(11–12), 1093–1099 (2010). • DBS applications in therapeutic drug monitoring.
CASGoogle Scholar
33. Manicke NE, Abu-Rabie P, Spooner N, Ouyang Z, Cooks RG. Quantitative analysis of therapeutic drugs in dried blood spot samples by paper spray mass spectrometry: an avenue to therapeutic drug monitoring. J. Am. Soc. Mass. Spectrom. 22(9), 1501–1507 (2011). • DBS applications in therapeutic drug monitoring.
Medline CASGoogle Scholar
34. Antunes MV, Charão MF, Linden R. Dried blood spots analysis with mass spectrometry: potentials and pitfalls in therapeutic drug monitoring. Clin. Biochem. 49(13–14), 1035–1046 (2016). • DBS applications in therapeutic drug monitoring.
Medline CASGoogle Scholar
35. Weber J, Oberfeld S, Bonse A, Telger K, Lingg R, Hempel G. Validation of a dried blood spot method for therapeutic drug monitoring of citalopram, mirtazapine and risperidone and its active metabolite 9-hydroxyrisperidone using HPLC–MS. J. Pharm. Biomed. Anal. 140, 347–354 (2017). • DBS applications in therapeutic drug monitoring.
Medline CASGoogle Scholar
36. Panchal T, Spooner N, Barfield M. Ensuring the collection of high-quality dried blood spot samples across multisite clinical studies. Bioanalysis 9(2), 209–213 (2017).
CASGoogle Scholar
37. Spooner N, Ramakrishnan Y, Barfield M, Dewit O, Miller S. Use of DBS sample collection to determine circulating drug concentrations in clinical trials: practicalities and considerations. Bioanalysis 2(8), 1515–1522 (2010).
CASGoogle Scholar
38. Knoop A, Geyer H, Lerch O, Rubio A, Schrader Y, Thevis M. Detection of anti-SARS-CoV-2 antibodies in dried blood spots utilizing manual or automated spot extraction and electrochemiluminescence immunoassay (ECLIA). Analyt. Sci.Adv. 2(9-10), 440–446 (2021).
Medline CASGoogle Scholar
39. Zava TT, Zava DT. Validation of dried blood spot sample modifications to two commercially available COVID-19 IgG antibody immunoassays. Bioanalysis 13(1), 13–28 (2020).
Google Scholar
40. Gaugler S, Sottas P, Blum K, Luginbühl M. Fully automated dried blood spot sample handling and extraction for serological testing of SARS-CoV-2 antibodies. Drug Test Anal. 13, 223–226 (2021).
Medline CASGoogle Scholar
41. Donna Grace Karp, Kenneth Danh DS. A serological assay to detect SARS-CoV-2 antibodies in at-home collected finger-prick dried blood spots. J. Chem. Inf. Model. 53(9), 1689–1699 (2016).
Google Scholar
42. Morley GL, Taylor S, Jossi S et al. Sensitive detection of SARS-CoV-2-specific-antibodies in dried blood spot samples. Emerg. Infect. Dis. 44(0), (2020). http://medrxiv.org/content/early/2020/07/02/2020.07.01.20144295.abstract
Google Scholar
43. Thevis M, Knoop A, Schaefer MS et al. Can dried blood spots (DBS) contribute to conducting comprehensive SARS-CoV-2 antibody tests? Drug Test. Anal. 12(7), 994–997 (2020).
Medline CASGoogle Scholar
44. Capiau S, Lambert WE, Stove CP. Hemato-critical issues in quantitative analysis of dried blood spots challenges and solutions. Bioanalysis 5(16), 2023–2041 (2013). •• Study of hematocrit bias and homogeneity of samples.
Google Scholar
45. Velghe S, Delahaye L, Stove CP. Is the hematocrit still an issue in quantitative dried blood spot analysis? J. Pharm. Biomed. Anal. 163, 188–196 (2019). •• Study of hematocrit bias and homogeneity of samples.
Medline CASGoogle Scholar
46. Leimin F JAL. Managing the effect of hematocrit on DBS analysis in a regulated environment. Bioanalysis 4(4), 345–347 (2012). •• Study of hematocrit bias and homogeneity of samples.
Google Scholar
47. De Vries R, Barfield M, Van De Merbel N et al. The effect of hematocrit on bioanalysis of DBS: Results from the EBF DBS-microsampling consortium. Bioanalysis 5(17), 2147–2160 (2013). •• Study of hematocrit bias and homogeneity of samples.
Google Scholar
48. De Vries R, Qin C, Boutet V, Kushon S, Rudge JB. A device for dried blood microsampling in quantitative bioanalysis: overcoming the issues associated with blood hematocrit. Bioanalysis. 7( 6), 653–659 (2015).
Google Scholar
49. Koo TS, Kim SJ, Lee J, Ha DJ, Baek M, Moon H. Quantification of lurasidone, an atypical antipsychotic drug, in rat plasma with high-performance liquid chromatography with tandem mass spectrometry. Biomed. Chromatogr. 25(12), 1389–1394 (2011). •• Quantitation of lurasidone in a biological matrix.
Medline CASGoogle Scholar
50. Atila Karaca S, Yeniceli Uğur D. Development of a validated high-performance liquid chromatographic method for the determination of lurasidone in pharmaceuticals. Marmara Pharm. J. 21(4), 931–937 (2017). •• Quantitation of lurasidone in a biological matrix.
Google Scholar
51. Katteboina MY, Pilli NR, Mullangi R, Seelam RR, Satla SR. LC–MS/MS assay for the determination of lurasidone and its active metabolite, ID-14283 in human plasma and its application to a clinical pharmacokinetic study. Biomed. Chromatogr. 30(7), 1065–1074 (2016). •• Quantitation of lurasidone in a biological matrix.
Medline CASGoogle Scholar
52. Chae YJ, Koo TS, Lee KR. A sensitive and selective LC–MS method for the determination of lurasidone in rat plasma, bile, and urine. Chromatographia 75(19–20), 1117–1128 (2012). •• Quantitation of lurasidone in a biological matrix.
CASGoogle Scholar
53. Patteet L, Maudens KE, Stove CP et al. The use of dried blood spots for quantification of 15 antipsychotics and 7 metabolites with ultra-high performance liquid chromatography-tandem mass spectrometry. Drug Test Anal. 7(6), 502–511 (2015). •• Quantitation of lurasidone in a biological matrix.
Medline CASGoogle Scholar
54. Hewawasam E, Liu G, Jeffery D.W et al. Estimation of the volume of blood in a small disc punched from a dried blood spot card. Eur. J. Lipid Sci. Technol. 120 (3) (2013).
Google Scholar
55. Patteet L, Maudens KE, Stove CP et al. The use of dried blood spots for quantification of 15 antipsychotics and 7 metabolites with ultra-high performance liquid chromatography-tandem mass spectrometry. Drug Test Anal. 7(6), 502–511 (2015).
Medline CASGoogle Scholar
56. Bioanalytical Method Validation Guidance for Industry. CDER, USFDA, (2018).
Google Scholar
57. Zakaria R, Allen KJ, Koplin JJ, Roche P, Greaves RF. Advantages and challenges of dried blood spot analysis by mass spectrometry across the total testing process. EJIFCC 27(4), 288–317 (2016).
Medline CASGoogle Scholar
58. Spooner N, Lad R, Barfield M. Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method. Anal. Chem. 81(4), 1557–1563 (2009).
Medline CASGoogle Scholar
59. Van Eeckhaut A, Lanckmans K, Sarre S, Smolders I, Michotte Y. Validation of bioanalytical LC–MS/MS assays: evaluation of matrix effects. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877(23), 2198–2207 (2009).
Medline CASGoogle Scholar
60. Chen G, Jirjees F, Al Bawab A, McElnay JC. Quantification of amlodipine in dried blood spot samples by high performance liquid chromatography tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1072(July 2017), 252–258 (2018).
Medline CASGoogle Scholar

Vol. 15, No. 24

Metrics

Downloaded 77 times

History

Received 24 July 2023

Accepted 3 November 2023

Published online 22 November 2023

Published in print December 2023

Information

Keywords

Author contributions

Experimental work was carried out by M Rajadhyaksha. Both authors made a considerable contribution in conceptualizing and writing the manuscript and approved it for publication.

Acknowledgments

The authors thank SPPSPTM, SVKM's Narsee Monjee Institute of Management Studies, Mumbai, India and Sitec Labs Ltd, Navi Mumbai, India for their support.

Financial disclosure

The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The study (protocol no. CPCSE/IAEC/P-62/2022) was approved by the Institutional Ethical Committee, Narsee Monjee Institute of Management Studies, India. The animal study protocol (CPCSEA/IAEC/P-62/2022) was reviewed and approved by the Institutional Ethic Committee, Narsee Monjee Institute of Management Studies, India.

PDF download